Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations.
Tejaswini KulkarniVincent G ValentineFei FeiThi K Tran-NguyenLuisa D Quesada-AriasTakudzwa MkorombindoHuy P PhamSierra C SimmonsKevin G DsouzaTracy LuckhardtSteven R DuncanPublished in: PloS one (2021)
Autoantibody reduction therapy is associated with rapid reduction of supplemental oxygen requirements and/or improved ability to ambulate in many AE-IPF patients. Facile anti-epithelial autoantibody assays may help identify those most likely to benefit from these treatments.
Keyphrases
- end stage renal disease
- idiopathic pulmonary fibrosis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- chronic obstructive pulmonary disease
- liver failure
- cystic fibrosis
- peritoneal dialysis
- prognostic factors
- high throughput
- quantum dots
- intensive care unit
- gold nanoparticles
- reduced graphene oxide
- patient reported
- mechanical ventilation
- metal organic framework